Activists Demand Lower Price for New Twice-Yearly HIV Jab Health activists are urging pharmaceutical giant Gilead Sciences to slash the price of its revolutionary, twice-yearly HIV prevention injection, lenacapavir. Fears are growing that its “beyond comprehension” cost will render it inaccessible for millions, particularly in high-burden countries like South Africa, undermining its potential to end…